Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope. - Baumgaertner P; Costa Nunes C; Cachot A; Maby-El Hajjami H; Cagnon L; Braun M; Derré L; Rivals JP; Rimoldi D; Gnjatic S; Abed Maillard S; Marcos Mondéjar P; et al. (Oncoimmunology, 2016)